$25.05 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest


About Merus

Merus NV is a biotechnology company based in the Netherlands. The Company develops differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Biclonics format. Its products include, among others, MCLA-134 that is designed to bind to a combination of two immunomodulatory targets expressed by T cells, as well as MCLA-145 that is designed to bind to a tumor-associated target with an immunomodulatory target involved in checkpoint inhibition.

Stock Analysis

last close $25.05
1-mo return 8%
3-mo return 54.1%
avg daily vol. 257.48T
52-week high 33.09
52-week low 13.47
market cap. $1.3B
forward pe -
annual div. -
roe -28.3%
ltg forecast -
dividend yield -
annual rev. $52M
inst own. 80%

Subscribe now for daily local and international financial news